Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bramitob/Tobrineb/Actitob versus TOBI in cystic fibrosis with chronic Pseudomonas aeruginosa infection
2006-006215-68Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tobramycin in cystic fibrosis (CF) and Pseudomonal infection (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Primary efficacy endpoint. Started Jun 2008; status: completed.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on 2006-006215-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006215-68.